| Entry |
|
|---|
| Name |
Piribedil (INN);
Trivastal (TN) |
|---|
| Formula |
C16H18N4O2
|
|---|
| Exact mass |
298.1430
|
|---|
| Mol weight |
298.34
|
|---|
| Structure |
|
|---|
| Class |
Neuropsychiatric agent
DG01472 Dopamine agonist
|
|---|
| Remark |
|
|---|
| Efficacy |
Antiparkinsonian, Dopamine receptor agonist |
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N04 ANTI-PARKINSON DRUGS
N04B DOPAMINERGIC AGENTS
N04BC Dopamine agonists
N04BC08 Piribedil
D07305 Piribedil (INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01472 Dopamine agonist
D07305 Piribedil
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D07305 Piribedil (INN)
DRD3
D07305 Piribedil (INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 22
1 C1x C 14.4200 -16.8700
2 N1y N 14.4200 -18.2700
3 C1x C 15.6324 -18.9700
4 C1x C 16.8449 -18.2700
5 N1y N 16.8449 -16.8700
6 C1x C 15.6324 -16.1700
7 C1b C 18.0760 -16.1590
8 C8y C 19.2811 -16.8547
9 C8x C 19.2816 -18.2696
10 C8x C 20.4942 -18.9693
11 C8y C 21.7064 -18.2689
12 C8y C 21.7060 -16.8540
13 C8x C 20.4934 -16.1543
14 O2x O 23.0523 -18.7058
15 C1x C 23.8836 -17.5608
16 O2x O 23.0516 -16.4163
17 C8y C 13.2076 -18.9700
18 N5x N 12.0121 -18.2796
19 C8x C 10.7996 -18.9794
20 C8x C 10.7994 -20.3794
21 C8x C 11.9949 -21.0698
22 N5x N 13.2074 -20.3700
BOND 25
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 2
10 9 10 1
11 10 11 2
12 11 12 1
13 12 13 2
14 8 13 1
15 11 14 1
16 14 15 1
17 15 16 1
18 12 16 1
19 2 17 1
20 17 18 2
21 18 19 1
22 19 20 2
23 20 21 1
24 21 22 2
25 17 22 1
|
|---|
